Loading...
XNASDERM
Market cap80mUSD
Jan 13, Last price  
3.78USD
1D
-4.25%
1Q
-34.31%
IPO
-57.44%
Name

Journey Medical Corp

Chart & Performance

D1W1MN
XNAS:DERM chart
P/E
—
P/S
1.00
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-15.37%
Rev. gr., 5y
13.34%
Revenues
79m
+7.48%
7,300,0007,300,00022,585,0004,541,00042,339,00034,921,00044,531,00063,134,00073,669,00079,181,000
Net income
-4m
L-87.00%
-31,875,000-78,399,000-89,084,000-303,261,000-221,540,0003,625,0005,283,000-43,994,000-29,628,000-3,853,000
CFO
5m
P
-31,404,000-48,442,000-74,111,000-103,963,000-213,098,0009,018,0005,132,000-2,181,000-13,534,0005,240,000
Earnings
Jun 25, 2025

Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
URL
https://journeymedicalcorp.com/
IPO date
Nov 12, 2021
Employees
20
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
79,181
7.48%
73,669
16.69%
Cost of revenue
34,201
41,718
Unusual Expense (Income)
NOPBT
44,980
31,951
NOPBT Margin
56.81%
43.37%
Operating Taxes
221
63
Tax Rate
0.49%
0.20%
NOPAT
44,759
31,888
Net income
(3,853)
-87.00%
(29,628)
-32.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,494
(742)
BB yield
-4.28%
2.20%
Debt
Debt current
3,099
3,031
Long-term debt
14,739
20,125
Deferred revenue
Other long-term liabilities
1,412
Net debt
(9,601)
(8,847)
Cash flow
Cash from operating activities
5,240
(13,534)
CAPEX
(20,000)
Cash from investing activities
(5,000)
(20,000)
Cash from financing activities
(4,804)
16,456
FCF
44,847
31,788
Balance
Cash
27,439
32,003
Long term investments
Excess cash
23,480
28,320
Stockholders' equity
(72,353)
(68,500)
Invested Capital
110,433
109,824
ROIC
40.64%
32.66%
ROCE
118.12%
77.32%
EV
Common stock shares outstanding
18,232
17,531
Price
5.76
200.00%
1.92
-64.31%
Market cap
105,019
212.00%
33,660
-63.87%
EV
95,418
24,813
EBITDA
48,835
36,316
EV/EBITDA
1.95
0.68
Interest
1,698
2,019
Interest/NOPBT
3.78%
6.32%